{"nctId":"NCT00579345","briefTitle":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","startDateStruct":{"date":"2007-10"},"conditions":["Influenza"],"count":1522,"armGroups":[{"label":"cTIV","type":"EXPERIMENTAL","interventionNames":["Biological: Cell culture derived seasonal trivalent influenza vaccine (cTIV)"]},{"label":"eTIV_a","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)."]},{"label":"FLU (cTIV or eTIV_a)","type":"EXPERIMENTAL","interventionNames":["Biological: cTIV or eTIV_a"]},{"label":"FLU (cTIV or eTIV_a) + PV","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: cTIV+PV OR eTIV_a+PV"]}],"interventions":[{"name":"Cell culture derived seasonal trivalent influenza vaccine (cTIV)","otherNames":[]},{"name":"Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).","otherNames":[]},{"name":"cTIV or eTIV_a","otherNames":[]},{"name":"cTIV+PV OR eTIV_a+PV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* participation in the V58P4 study\n* mentally competent to understand the nature, the scope and the consequences of the study\n* able and willing to give written informed consent prior to study entry\n* available for all the visits scheduled in the study\n\nExclusion Criteria:\n\n* receipt of another investigational agent within 90 days prior to, or before completion of the safety follow-up period in another study, whichever is longer, prior to Visit 7 and unwilling to refuse participation in another clinical study through the end of the present study\n* history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine components\n* any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or experienced fever (i.e., axillary temperature ≥ 38°C) within the 5 days prior to Visit 7\n* pregnant/breast feeding women, or women of childbearing potential who refuse to use a reliable contraceptive method during the three weeks after vaccination","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Unrandomized Participants Reporting Local and Systemic Reactions.","description":"Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"37","spread":null},{"groupId":"OG003","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Randomized Participants Reporting Local and Systemic Reactions.","description":"Safety and tolerability evaluation, within one week of single intramuscular injection of influenza vaccines (cell-culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV\\_a) when administered alone or concomitantly with a pneumococcal vaccine (PV)). Local reactions reported for Influenza Vaccine Injection Site.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"32","spread":null},{"groupId":"OG004","value":"20","spread":null},{"groupId":"OG005","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"23","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"22","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Randomized Participants Reporting Local and Systemic Reactions.","description":"Safety and tolerability evaluation of influenza vaccines, within one week of single intramuscular injection. Local reactions reported for Influenza Vaccine Injection site.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Antibody Response as Assessed by Hemagglutination Inhibition Assay.","description":"Immunogenicity (seroconversion or significant increase in antibody titer and HI titer ≥1:40) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the Committee for Medicinal Products for Human Use (CHMP) criteria (CPMP/BWP/214/96).\n\nSeroconversion was defined as negative pre-vaccination titer (\\<10)/postvaccination titer ≥40. Significant increase in antibody titer was defined as at least a fourfold increase from non-negative baseline (≥10).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"62","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMR Day 22/Day1) After Single Dose of Influenza Vaccine.","description":"Immunogenicity (geometric mean titer ratio) of cell cultured and egg based trivalent influenza vaccine three weeks after a single injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the CHMP criteria (CPMP/BWP/214/96).\n\nCHMP Criteria fulfilled if the Geometric Mean titer Ratio (GMR) is \\> 2.5.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.38","spread":null},{"groupId":"OG002","value":"7.75","spread":null},{"groupId":"OG003","value":"5.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.63","spread":null},{"groupId":"OG001","value":"2.33","spread":null},{"groupId":"OG002","value":"2.65","spread":null},{"groupId":"OG003","value":"2.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":null},{"groupId":"OG001","value":"2.33","spread":null},{"groupId":"OG002","value":"2.51","spread":null},{"groupId":"OG003","value":"2.97","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity Assessment by Geometric Mean Titers (GMT).","description":"Non-inferiority of the influenza vaccine FLU (cell-culture derived seasonal trivalent influenza vaccine (cTIV); and influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV\\_a)) when administered alone versus administered concomitantly with pneumococcal vaccine (FLU + PV) is met if lower limit of the 2-sided 95% confidence interval (CI) of postvaccination (Day 22) Geometric Mean Titer ratio (FLU+PV/FLU) is greater than 0.5.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":550},"commonTop":["Injection site pain","Injection site erythema","Malaise","Headache","Injection site induration"]}}}